糖尿病新世界
糖尿病新世界
당뇨병신세계
Diabetes New World
2015年
21期
37-39
,共3页
2型糖尿病肾脏病%羟苯磺酸钙%替米沙坦
2型糖尿病腎髒病%羥苯磺痠鈣%替米沙坦
2형당뇨병신장병%간분광산개%체미사탄
Type 2 diabetic kidney disease%Calcium dobesilate%Telmisartan
目的 探讨应用羟苯磺酸钙联合替米沙坦这两种药物治疗2型糖尿病肾病的临床效果. 方法 选取该院于2014年1月—2015年5月期间所收治的2型糖尿病肾病患者60例作为该次研究的对象,根据治疗方法的不同将患者以实验组和对照组进行划分,每组各30例. 两组患者均接受常规降血糖治疗和低蛋白饮食,实验组采用口服羟苯磺酸钙胶囊联合替米沙坦治疗,对照组单用替米沙坦治疗. 比较两组患者治疗前后血肌酐(Scr)、血尿素氮(BUN)、尿白蛋白排泄率 (UAER)以及糖化血红蛋白(HbA1c)水平变化情况. 结果 经过持续12个星期治疗后,发现两组患者治疗前后Scr、BUN水平变化比较差异无统计学意义(P>0.05);两组患者治疗后UAER水平与治疗之前比较均有显著改善,差异有统计学意义(P<0.05);两组患者治疗前后HbA1c水平比较差异无统计学意义(P>0.05). 治疗后实验组UAER水平改善情况优于对照组,差异有统计学意义(P<0.05);治疗后实验组与对照组HbA1c水平比较差异无统计学意义(P>0.05).结论 临床应用羟苯磺酸钙联合替米沙坦这两种药物治疗2型糖尿病肾病能有效降低患者的尿白蛋白排泄率, 具有较高的安全性,值得推广借鉴.
目的 探討應用羥苯磺痠鈣聯閤替米沙坦這兩種藥物治療2型糖尿病腎病的臨床效果. 方法 選取該院于2014年1月—2015年5月期間所收治的2型糖尿病腎病患者60例作為該次研究的對象,根據治療方法的不同將患者以實驗組和對照組進行劃分,每組各30例. 兩組患者均接受常規降血糖治療和低蛋白飲食,實驗組採用口服羥苯磺痠鈣膠囊聯閤替米沙坦治療,對照組單用替米沙坦治療. 比較兩組患者治療前後血肌酐(Scr)、血尿素氮(BUN)、尿白蛋白排洩率 (UAER)以及糖化血紅蛋白(HbA1c)水平變化情況. 結果 經過持續12箇星期治療後,髮現兩組患者治療前後Scr、BUN水平變化比較差異無統計學意義(P>0.05);兩組患者治療後UAER水平與治療之前比較均有顯著改善,差異有統計學意義(P<0.05);兩組患者治療前後HbA1c水平比較差異無統計學意義(P>0.05). 治療後實驗組UAER水平改善情況優于對照組,差異有統計學意義(P<0.05);治療後實驗組與對照組HbA1c水平比較差異無統計學意義(P>0.05).結論 臨床應用羥苯磺痠鈣聯閤替米沙坦這兩種藥物治療2型糖尿病腎病能有效降低患者的尿白蛋白排洩率, 具有較高的安全性,值得推廣藉鑒.
목적 탐토응용간분광산개연합체미사탄저량충약물치료2형당뇨병신병적림상효과. 방법 선취해원우2014년1월—2015년5월기간소수치적2형당뇨병신병환자60례작위해차연구적대상,근거치료방법적불동장환자이실험조화대조조진행화분,매조각30례. 량조환자균접수상규강혈당치료화저단백음식,실험조채용구복간분광산개효낭연합체미사탄치료,대조조단용체미사탄치료. 비교량조환자치료전후혈기항(Scr)、혈뇨소담(BUN)、뇨백단백배설솔 (UAER)이급당화혈홍단백(HbA1c)수평변화정황. 결과 경과지속12개성기치료후,발현량조환자치료전후Scr、BUN수평변화비교차이무통계학의의(P>0.05);량조환자치료후UAER수평여치료지전비교균유현저개선,차이유통계학의의(P<0.05);량조환자치료전후HbA1c수평비교차이무통계학의의(P>0.05). 치료후실험조UAER수평개선정황우우대조조,차이유통계학의의(P<0.05);치료후실험조여대조조HbA1c수평비교차이무통계학의의(P>0.05).결론 림상응용간분광산개연합체미사탄저량충약물치료2형당뇨병신병능유효강저환자적뇨백단백배설솔, 구유교고적안전성,치득추엄차감.
Objective To explore the application of calcium dobesilate combined with telmisartan in the two drug treatment of type 2 diabetic nephropathy clinical effect. Methods 2 diabetic nephropathy patients in our hospital from January 2014 to May 2015 were selected as the object of this study, according to different treatment methods, patients in the experimental group and the control group were divided into 30 cases in each group. Two groups of patients were treated with conventional hypoglycemic therapy and low protein diet, the experimental group with oral calcium dobesilate capsule combined with telmisartan treatment, and the patients in control group were treated with telmisartan alone. Blood creatinine (Scr), blood urea nitrogen (BUN), urinary albumin excretion rate (UAER) and glycosylated hemoglobin (HbA1c) levels were compared between the two groups. Results after 12 weeks of treatment, there was no significant difference in BUN and Scr levels be-tween the two groups before and after treatment (P >0.05);the difference was statistically significant (P <0.05);the differ-ence was not statistically significant (P> 0.05) before and after treatment in two groups. After treatment, the UAER level of the experimental group was better than the control group, the difference was statistically significant (P <0.05);there was no significant difference between the experimental group and the control group (P >0.05). Conclusion The clinical application of calcium dobesilate combined with telmisartan in the two drug treatment of type 2 diabetic nephropathy can effectively re-duce the rate of urinary albumin excretion in patients, with high security, it is worth learning to promote.
